New Nipocalimab Data Published in MAbs Journal Details Differentiated Molecular Design, Clinical Profile and Potential of Nipocalimab to Treat IgG-Driven Alloantibody and Autoantibody Diseases
February 15, 2025
February 15, 2025
NEW BRUNSWICK, New Jersey, Feb. 15 -- Johnson and Johnson issued the following news release:
* * *
New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases
Published results reinforce the high-affinity binding and immunoselective properties of nipocalimab, which has been shown to reduce IgG levels by >75%, including auto . . .
* * *
New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases
Published results reinforce the high-affinity binding and immunoselective properties of nipocalimab, which has been shown to reduce IgG levels by >75%, including auto . . .